Lactic acid bacteria (LAB) and their exopolysaccharides (EPS) are recognized to promote intestinal barrier function by mechanisms that remain incompletely understood. Herein, we sought to identify the roles of exopolysaccharides from Lactobacillus plantarum NCU116 (EPS116) in intestinal barrier function. Our data showed that EPS116 attenuated dextran sodium sulfate (DSS) induced colitis and promoted epithelial barrier function and the expression of tight junction (TJ) proteins in vivo and in vitro. Moreover, chromatin immunoprecipitation data showed that EPS116 facilitated STAT3 (signal transducer and activator of transcription 3) binding to the promoter of occludin and ZO-1. Furthermore, knockdown of STAT3 in Caco-2 cell with EPS116 treatment led to decreased expression of occludin and ZO-1 and increased intestinal permeability, suggesting that the regulation of epithelial barrier function by EPS116 should be STAT3 dependent. Thus, our data revealed a novel mechanism that EPS116 inhibited intestinal inflammation via regulating intestinal epithelial barrier function.
Exopolysaccharides (EPS) from lactic acid bacteria (LAB) have been reported to play vital parts in the modulation of cell-cycle and apoptosis in cancer cells. However, the mechanisms by which EPS regulate the proliferation and apoptosis of cancer cells remain incompletely understood. We thus used different cancer cells to evaluate the anticancer ability and to investigate the underlying molecular mechanism of EPS from Lactobacillus plantarum NCU116 (EPS116). Our studies showed that EPS116 inhibited the proliferation of cancer cells in a cell type manner, and remarkably repressed the growth and survival of CT26 through induction of apoptosis. Moreover, EPS116 increased the expression of pro-apoptotic genes, including Fas, Fasl and c-Jun, induced the phosphorylation of c-Jun in CT26 cells. Furthermore, TLR2 (Toll like receptor 2) was upregulated by EPS116, and the CT26 cells with TLR2 knockdown were found to be insensitive to EPS116, suggesting that the anti-cancer activity of EPS116 may be TLR2-dependent. Taken together, the suppressive efficacy of EPS116 on the proliferation of CT26 cells may be mediated via TLR2 and the activation of c-Jun dependent Fas/Fasl-mediated apoptotic pathway. Our study has, for the first time, shown that EPS from LAB induced c-Jun dependent Fas/Fasl-mediated apoptosis via TLR2 in CT26 cells.
Regeneration
of epithelia is crucial for maintaining the intestinal
barrier and homeostasis. Our previous work showed that exopolysaccharides
from Lactobacillus plantarum NCU116
(EPS116) regulated the barrier function and homeostasis of the intestine;
however, the relevant mechanisms remain obscure. Therefore, we sought
to explore the role of EPS116 in promoting intestinal epithelial regeneration.
Our data showed that the administration of EPS116 markedly ameliorated
inflammatory bowel disease-related phenotypes and promoted the regeneration
of crypts in the colon of colitis mice. The results of immunofluorescence
and reverse transcription-quantitative polymerase chain reaction experiments
indicated that EPS116 strikingly increased the number of intestinal
stem cells (ISCs) and the expression of differentiation markers for
goblet cells, enterocytes, and enteroendocrine cells in the mouse
colon. Intestinal microbiota analysis showed that EPS116 increased
microbial populations associated with intestinal regeneration and
glycan metabolism. Therefore, the present study revealed a novel model
that EPS116 promoted the intestinal homeostasis through modulating
the proliferation and differentiation of ISCs and altering the gut
microbiota profile.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.